Uveitis Treatment Market (By Type: Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, And Panuveitis; By Treatment Type: Anti-Inflammatory Medications, Antibiotic/Antiviral Medications, And Immunosuppressive Medications; By Geography: North America, Europe, Asia-Pacific, and RoW) Global Scenario, Market Size, Outlook, Trend and Forecast, 2015-2024
Global Uveitis Treatment Market is estimated to reach $1,142 million by 2024; growing at a CAGR of 7.5% from 2016 to 2024. Uveitis is a type of inflammatory disease that induces swelling and destroys eye tissues of one or both eyes. The primary causes of uveitis include toxins that penetrate the eye, infections occurred within eye or any other body parts, bruises to eyes, and attack from own immune system (autoimmunity). Symptoms comprises redness of the eye, blurred vision, eye pain, sensitivity to eye (photophobia), and dark and floating spots in the vision (floaters).
Increasing demand for generic drugs, rising R&D budget for innovations in drugs and treatments, and growing occurrence of uveitis diseases are the major factors supporting the growth of the global uveitis treatment market. However, lack of knowledge, high costs of medications, and possibility of side effects could hamper the growth of the market. Additionally, rising awareness among end-users and advancements in of drugs and treatments for uveitis diseases would provide several growth opportunities in coming years.
The global uveitis treatment market is bifurcated into type, treatment type, and geography. The type segment is categorized as posterior uveitis, anterior uveitis, intermediate uveitis, and panuveitis. Treatment type segment is further sub-segmented into immunosuppressive medications, anti-inflammatory medications, and antibiotic/antiviral medications.
Based on geography, global uveitis treatment market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America is further bifurcated in U.S., Canada, and Mexico whereas Europe segment consist of UK, Russia, Germany, France, Italy, and others. Asia-Pacific is segmented into India, China, Japan, South Korea, and others while RoW is bifurcated into South America, Middle East, and Africa.
The key market players include Alimera Sciences Inc., Novartis AG (ALCON), AbbVie Inc., Valeant Pharmaceutical International Inc., Santen pharmaceutical Co., Ltd., EyeGate Pharmaceuticals Inc., Allergan Inc., Bausch & Lomb Incorporated., Amdipharm Mercury Company Ltd., and pSivida Corp., among others.
THE KEY TAKEAWAYS FROM THE REPORT
Type Segment
Increasing demand for generic drugs, rising R&D budget for innovations in drugs and treatments, and growing occurrence of uveitis diseases are the major factors supporting the growth of the global uveitis treatment market. However, lack of knowledge, high costs of medications, and possibility of side effects could hamper the growth of the market. Additionally, rising awareness among end-users and advancements in of drugs and treatments for uveitis diseases would provide several growth opportunities in coming years.
The global uveitis treatment market is bifurcated into type, treatment type, and geography. The type segment is categorized as posterior uveitis, anterior uveitis, intermediate uveitis, and panuveitis. Treatment type segment is further sub-segmented into immunosuppressive medications, anti-inflammatory medications, and antibiotic/antiviral medications.
Based on geography, global uveitis treatment market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America is further bifurcated in U.S., Canada, and Mexico whereas Europe segment consist of UK, Russia, Germany, France, Italy, and others. Asia-Pacific is segmented into India, China, Japan, South Korea, and others while RoW is bifurcated into South America, Middle East, and Africa.
The key market players include Alimera Sciences Inc., Novartis AG (ALCON), AbbVie Inc., Valeant Pharmaceutical International Inc., Santen pharmaceutical Co., Ltd., EyeGate Pharmaceuticals Inc., Allergan Inc., Bausch & Lomb Incorporated., Amdipharm Mercury Company Ltd., and pSivida Corp., among others.
THE KEY TAKEAWAYS FROM THE REPORT
- The report will provide detailed analysis of Uveitis Treatment Market with respect to major segments such as type, and treatment type
- The report will include the qualitative and quantitative analysis with market estimation over 2015-2024 and compound annual growth rate (CAGR) between 2016 and 2024
- Comprehensive analysis of market dynamics including factors and opportunities will be provided in the report
- An exhaustive regional analysis of Uveitis Treatment Market has been included in the report
- Profile of the key players in Uveitis Treatment Market will be provided, which include key financials, product & services, new developments and business strategies
Type Segment
- Posterior Uveitis
- Anterior Uveitis
- Intermediate Uveitis
- Panuveitis
- Immunosuppressive Medications
- Anti-Inflammatory Medications
- Antibiotic/Antiviral Medications
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Russia
- Germany
- France
- Italy
- Others
- Asia-Pacific
- India
- China
- Japan
- South Korea
- Others
- RoW
- South America
- Middle East
- Africa
CHAPTER 1 PREFIX
1.1 Market Scope
1.2 Report Description
1.3 Research Methodology
1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 In-house Data Modeling
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET OUTLINE
3.1 Market Inclination, Trend, Outlook and Viewpoint
3.2 Market Share Analysis: Company’s Competitive Scenario
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.1 Impact Analysis
3.3.2 Restraints
3.3.2.1 Impact Analysis
3.3.3 Opportunities
CHAPTER 4 UVEITIS TREATMENT MARKET BY TYPE: MARKET SIZE AND FORECAST, 2015 – 2024
4.1 Overview
4.2 Anterior Uveitis
4.2.1 Current Trend and Analysis
4.2.2 Market Size and Forecast
4.3 Posterior Uveitis
4.3.1 Current Trend and Analysis
4.3.2 Market Size and Forecast
4.4 Intermediate Uveitis
4.4.1 Current Trend and Analysis
4.4.2 Market Size and Forecast
4.5 Panuveitis
4.5.1 Current Trend and Analysis
4.5.2 Market Size and Forecast
CHAPTER 5 UVEITIS TREATMENT MARKET BY TREATMENT TYPE: MARKET SIZE AND FORECAST, 2015 – 2024
5.1 Overview
5.2 Anti-Inflammatory Medications
5.2.1 Current Trend and Analysis
5.2.2 Market Size and Forecast
5.3 Antibiotic/Antiviral Medications
5.3.1 Current Trend and Analysis
5.3.2 Market Size and Forecast
5.4 Immunosuppressive Medications
5.4.1 Current Trend and Analysis
5.4.2 Market Size and Forecast
CHAPTER 6 UVEITIS TREATMENT MARKET BY GEOGRAPHY: MARKET SIZE AND FORECAST, 2015 – 2024
6.1 Overview
6.2 North America
6.2.1 Current Trend and Analysis
6.2.2 Market Size and Forecast
6.2.3 US
6.2.3.1 Market Size and Forecast
6.2.4 Canada
6.2.4.1 Market Size and Forecast
6.2.5 Mexico
6.2.5.1 Market Size and Forecast
6.3 Europe
6.3.1 Current Trend and Analysis
6.3.2 Market Size and Forecast
6.3.3 Germany
6.3.3.1 Market Size and Forecast
6.3.4 France
6.3.4.1 Market Size and Forecast
6.3.5 United Kingdom
6.3.5.1 Market Size and Forecast
6.3.6 Italy
6.3.6.1 Market Size and Forecast
6.3.7 Russia
6.3.7.1 Market Size and Forecast
6.3.8 Others
6.3.8.1 Market Size and Forecast
6.4 Asia-Pacific
6.4.1 Current Trend and Analysis
6.4.2 Market Size and Forecast
6.4.3 China
6.4.3.1 Market Size and Forecast
6.4.4 India
6.4.4.1 Market Size and Forecast
6.4.5 Japan
6.4.5.1 Market Size and Forecast
6.4.6 South Korea
6.4.6.1 Market Size and Forecast
6.4.7 Others
6.4.7.1 Market Size and Forecast
6.5 RoW
6.5.1 Current Trend and Analysis
6.5.2 Market Size and Forecast
6.5.3 Middle East
6.5.3.1 Market Size and Forecast
6.5.4 South America
6.5.4.1 Market Size and Forecast
6.5.5 Africa
6.5.5.1 Market Size and Forecast
CHAPTER 7 COMPANY PROFILES
7.1 Novartis AG (ALCON)
7.2 Valeant Pharmaceutical International Inc.
7.3 EyeGate Pharmaceuticals Inc.
7.4 Alimera Sciences Inc.
7.5 Santen pharmaceutical Co., Ltd.
7.6 Bausch & Lomb Incorporated.
7.7 AbbVie Inc.
7.8 Allergan Inc.
7.9 Amdipharm Mercury Company Ltd.
7.10 pSivida Corp.
1.1 Market Scope
1.2 Report Description
1.3 Research Methodology
1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 In-house Data Modeling
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET OUTLINE
3.1 Market Inclination, Trend, Outlook and Viewpoint
3.2 Market Share Analysis: Company’s Competitive Scenario
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.1 Impact Analysis
3.3.2 Restraints
3.3.2.1 Impact Analysis
3.3.3 Opportunities
CHAPTER 4 UVEITIS TREATMENT MARKET BY TYPE: MARKET SIZE AND FORECAST, 2015 – 2024
4.1 Overview
4.2 Anterior Uveitis
4.2.1 Current Trend and Analysis
4.2.2 Market Size and Forecast
4.3 Posterior Uveitis
4.3.1 Current Trend and Analysis
4.3.2 Market Size and Forecast
4.4 Intermediate Uveitis
4.4.1 Current Trend and Analysis
4.4.2 Market Size and Forecast
4.5 Panuveitis
4.5.1 Current Trend and Analysis
4.5.2 Market Size and Forecast
CHAPTER 5 UVEITIS TREATMENT MARKET BY TREATMENT TYPE: MARKET SIZE AND FORECAST, 2015 – 2024
5.1 Overview
5.2 Anti-Inflammatory Medications
5.2.1 Current Trend and Analysis
5.2.2 Market Size and Forecast
5.3 Antibiotic/Antiviral Medications
5.3.1 Current Trend and Analysis
5.3.2 Market Size and Forecast
5.4 Immunosuppressive Medications
5.4.1 Current Trend and Analysis
5.4.2 Market Size and Forecast
CHAPTER 6 UVEITIS TREATMENT MARKET BY GEOGRAPHY: MARKET SIZE AND FORECAST, 2015 – 2024
6.1 Overview
6.2 North America
6.2.1 Current Trend and Analysis
6.2.2 Market Size and Forecast
6.2.3 US
6.2.3.1 Market Size and Forecast
6.2.4 Canada
6.2.4.1 Market Size and Forecast
6.2.5 Mexico
6.2.5.1 Market Size and Forecast
6.3 Europe
6.3.1 Current Trend and Analysis
6.3.2 Market Size and Forecast
6.3.3 Germany
6.3.3.1 Market Size and Forecast
6.3.4 France
6.3.4.1 Market Size and Forecast
6.3.5 United Kingdom
6.3.5.1 Market Size and Forecast
6.3.6 Italy
6.3.6.1 Market Size and Forecast
6.3.7 Russia
6.3.7.1 Market Size and Forecast
6.3.8 Others
6.3.8.1 Market Size and Forecast
6.4 Asia-Pacific
6.4.1 Current Trend and Analysis
6.4.2 Market Size and Forecast
6.4.3 China
6.4.3.1 Market Size and Forecast
6.4.4 India
6.4.4.1 Market Size and Forecast
6.4.5 Japan
6.4.5.1 Market Size and Forecast
6.4.6 South Korea
6.4.6.1 Market Size and Forecast
6.4.7 Others
6.4.7.1 Market Size and Forecast
6.5 RoW
6.5.1 Current Trend and Analysis
6.5.2 Market Size and Forecast
6.5.3 Middle East
6.5.3.1 Market Size and Forecast
6.5.4 South America
6.5.4.1 Market Size and Forecast
6.5.5 Africa
6.5.5.1 Market Size and Forecast
CHAPTER 7 COMPANY PROFILES
7.1 Novartis AG (ALCON)
7.2 Valeant Pharmaceutical International Inc.
7.3 EyeGate Pharmaceuticals Inc.
7.4 Alimera Sciences Inc.
7.5 Santen pharmaceutical Co., Ltd.
7.6 Bausch & Lomb Incorporated.
7.7 AbbVie Inc.
7.8 Allergan Inc.
7.9 Amdipharm Mercury Company Ltd.
7.10 pSivida Corp.
